ArticleDeutsches Arzteblatt international2008
Pancreatic cancer--low survival rates.
Article in Deutsches Arzteblatt international, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of pancreas and biliary tract cancer.Clinical & experimental metastasis · 2018Trial
- Effectiveness of multidisciplinary team collaboration in focal pancreatic lesion management: a systematic review.Abdominal radiology (New York) · 2026Review
- Recent Developments in the Synthesis of Benzothiazoles and their Anti-cancer Mechanistic Discoveries.Current pharmaceutical design · 2025Review
- DNA methylation biomarker analysis from low-survival-rate cancers based on genetic functional approaches.Frontiers in bioinformatics · 2025Article
- Near-infrared imaging of head and neck squamous cell carcinoma using indocyanine green that targets theJournal of biomedical optics · 2024Article
- Chlorambucil-Bearing Hybrid Molecules in the Development of Potential Anticancer Agents.Molecules (Basel, Switzerland) · 2023Review
- Article
- Hyperthermic intra-operative intraperitoneal chemotherapy as an adjuvant to pancreatic cancer resection.Journal of gastrointestinal oncology · 2021Article
- Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review.Oncology letters · 2021Article
- miR-597-5p inhibits cell growth and promotes cell apoptosis by targeting ELK1 in pancreatic cancer.Human cell · 2020Article
- Article
- Jack of many trades: Multifaceted role of neuropilins in pancreatic cancer.Cancer medicine · 2018Review
- Expression of PRR11 protein and its correlation with pancreatic cancer and effect on survival.Oncology letters · 2017Article
- Epidemiology of pancreatic cancer.World journal of gastroenterology · 2016Review
- Novel regulatory role of neuropilin-1 in endothelial-to-mesenchymal transition and fibrosis in pancreatic ductal adenocarcinoma.Oncotarget · 2016Article
- Preliminary results of hyperthermic intraperitoneal intraoperative chemotherapy as an adjuvant in resectable pancreatic cancer.Gastroenterology research and practice · 2012Article
- Neoadjuvant therapy in patients with pancreatic cancer: a disappointing therapeutic approach?Cancers · 2011Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCancers of the pancreas are identified in 11 800 to 13 500 patients each year in Germany. Epidemiological studies prove smoking and chronic alcohol consumption as causes of about 30% of pancreatic cancers.
methodsSelective literature review.
resultsOnly patients within TNM stage I and II have after oncologic tumor extirpation a chance for long term survival. Controlled prospective clinical trials demonstrated adjuvant chemotherapy yielding an additional significant survival benefit. The 3- and 5-year-survival after R0-resection and adjuvant chemotherapy are about 30% and below 15% respectively. Using the criteria of observed 5-year-survival less than 2% of all pancreatic cancer patients are alive. After R0-resection the median survival time is between 17 and 28 months, after R1/2-resection between 8 and 22 months. DISCUSSION: Pancreatic cancer is even today for more than 95% of the patients incurable. Strategies to prevent pancreatic cancer are intended to stop smoking and chronic alcohol consumption and early surgical extirpation of cystic neoplastic lesions. For patients with established pancreatic cancer risk a follow-up protocol is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.